Long‐term efficacy and safety during open‐label erenumab treatment in Japanese patients with episodic migraine

OBJECTIVE: To assess long‐term (up to 2 years) efficacy, tolerability, and safety of erenumab for the prevention of episodic migraine (EM) in Japanese patients. BACKGROUND: Previously published results from the double‐blind treatment phase (DBTP) of a phase 2 clinical study have demonstrated the eff...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Headache
Autors principals: Sakai, Fumihiko, Takeshima, Takao, Tatsuoka, Yoshihisa, Hirata, Koichi, Cheng, Sunfa, Numachi, Yotaro, Peng, Cheng, Xue, Fei, Mikol, Daniel D.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2021
Matèries:
Research Submissions
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8251924/
https://ncbi.nlm.nih.gov/pubmed/33764538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/head.14096
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars